# Respiratory enterovirus D68: virology, clinical surveillance, host-pathogen interactions, and therapeutic prospects

**Authors:** Yanshan Gui, Bing Han, Jialong Wei, Danlei Sun, Laixian Zhou, Shuchen Yuan, Wenzhan Xie, Hui Feng

PMC · DOI: 10.3389/fcimb.2026.1774711 · 2026-03-05

## TL;DR

This paper reviews the virology, immune interactions, and treatment prospects for enterovirus D68, which causes severe respiratory illnesses and acute flaccid myelitis in children.

## Contribution

The paper provides a comprehensive overview of EV-D68's clinical patterns, immune evasion strategies, and recent antiviral developments.

## Key findings

- EV-D68 has shifted from causing mild infections to biennial outbreaks with severe respiratory illness and AFM.
- Current clinical detection is challenging, and no FDA-approved treatments or vaccines exist.
- Research is needed to understand immune responses and develop effective diagnostics and therapies.

## Abstract

Enterovirus D68 (EV-D68), a unique enterovirus resembling human rhinoviruses, was long considered to cause only sporadic outbreaks of mild, self-limiting respiratory infections mainly in children. However, over the past decade, EV-D68 has exhibited a biennial outbreak pattern across multiple regions worldwide, coinciding with an increased incidence of severe respiratory illnesses and cases of acute flaccid myelitis (AFM) in children. The immune system plays a crucial role in providing rapid and effective defense. Nonetheless, our knowledge of the complex interactions between EV-D68 and the host immune responses is still very limited. Additionally, clinical detection of EV-D68 remains challenging, and there are no FDA-approved vaccines or antiviral treatments available. Therefore, ongoing research should focus on understanding the pathogenic mechanisms of EV-D68, as well as the development of reliable diagnostic methods and therapeutic options to control EV-D68 spread. This review intends to examine the initiatives undertaken for clinical surveillance of EV-D68 outbreaks, the immune responses elicited by EV-D68, and its strategies for immune evasion. Additionally, it explores recent advancements in antiviral drug development, thereby providing a comprehensive overview of current knowledge and identifying prospective directions for future research.

## Linked entities

- **Diseases:** acute flaccid myelitis (MONDO:0100115)

## Full-text entities

- **Diseases:** respiratory infections (MESH:D012141), respiratory illnesses (MESH:D012140), AFM (MESH:C000629404)
- **Species:** Homo sapiens (human, species) [taxon 9606], Enterovirus (genus) [taxon 12059], enterovirus D68 (no rank) [taxon 42789]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12999577/full.md

---
Source: https://tomesphere.com/paper/PMC12999577